PARRC
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- NCT06770582 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on PARRC (mitomycin, pembrolizumab and 3 more in Non-Muscle Invasive Bladder Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PARRC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma; Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage I Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection; Cisplatin; Computed Tomography; Fluorouracil; Gemcitabine; Magnetic Resonance Imaging; Mitomycin; Pembrolizumab; Questionnaire Administration; Radiation Therapy
- Arms
- Arm 1 (Chemotherapy and radiation) · Active comparator
- Arm 2 (Pembrolizumab and radiation) · Experimental
- Enrollment
- 160 (estimated)
- Primary outcomes
- Bladder intact event-free survival (BIEFS)
- Global quality of life
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 3, 2025
- Primary completion
- Feb 1, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06770582 · updated Oct 19, 2026